FDA peptide status and safety signals for Semaglutide

Clinical Question

What is the current FDA regulatory status for commonly used peptides, and what safety signals have emerged from clinical trial and postmarketing surveillance data?

Evidence Snapshot

• Regulatory Status: Multiple peptides including BPC-157, TB-500, and CJC-1295 are currently listed under FDA Category 2, indicating significant safety risks or lack of safety data.
• Safety Signals: Semaglutide postmarketing data reveals strong signals for gastrointestinal events and emerging signals for ocular and pulmonary complications.
• Clinical Trials: Phase III data for Semaglutide and Tirzepatide demonstrate significant weight loss and MACE reduction, while Thymosin Alpha-1 failed to reduce mortality in sepsis trials.
• Regulatory Actions: Warning letters issued to entities such as Tailor Made Compounding and Predator Nutrition regarding the distribution of unapproved peptide substances.

What the Research Shows

Regulatory Landscape and Compounding Restrictions As of March 2026, the FDA has classified several peptides under Category 2 for 503A compounding, which renders them ineligible for routine compounding due to safety risks or lack of established clinical need. BPC-157 was designated as Category 2 in September 2023, with the FDA citing immunogenicity concerns and a deficit of safety data. Similarly, TB-500 is listed under Category 2 due to immunogenicity risks and a lack of human exposure data.

Several peptides previously nominated for compounding have seen their nominations withdrawn or removed. CJC-1295 was removed in September 2024 following FDA concerns over safety issues such as increased heart rate. Ipamorelin, AOD-9604, and Selank also saw nominations withdrawn in September 2024. GHK-Cu and GHRP-2 remain in Category 2, with the FDA specifically noting immunogenicity risks for both substances.

Thymosin Alpha-1 presents a complex regulatory profile. While approved in over 35 countries as Zadaxin, it is not FDA-approved. It was moved from Category 2 to a status of "removed pending advisory review" in September 2024, though it remains a substance of concern under interim policy.

Safety Signals and Postmarketing Surveillance Pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) for Semaglutide indicates 187,757 total reports through 2023. Strong signals (elevated ROR) are established for nausea, vomiting, and delayed gastric emptying. The latter has clinical implications for the absorption of oral medications and pre-surgical management.

Emerging and moderate signals for Semaglutide include:

• Gastrointestinal: Acute pancreatitis (PRR elevated) and postmarketing reports of intestinal obstruction/ileus.
• Hepatobiliary: Cholelithiasis and cholecystitis, associated with rapid weight loss.
• Renal: Acute kidney injury, often occurring in the context of GI-related dehydration.
• Ocular: Nonarteritic Anterior Ischemic Optic Neuropathy (NAION), with 96 cases reported through December 2024, prompting an EMA review in January 2025.
• Pulmonary: Pulmonary aspiration risk during general anesthesia, leading to a 2025 update to the Ozempic label.

Clinical Trial Outcomes In Phase III trials (STEP 1), Semaglutide demonstrated a 14.9% weight loss, while the SELECT trial showed a 20% reduction in Major Adverse Cardiovascular Events (MACE). Tirzepatide demonstrated superior weight loss (22.5% in SURMOUNT-1) compared to Semaglutide in head-to-head Phase IIIb trials (SURMOUNT-5). Retatrutide Phase II data showed 24.2% weight loss at 12mg, with Phase III (TRIUMPH-3) trials currently recruiting. In contrast, Thymosin Alpha-1 failed to demonstrate a mortality reduction in the Phase III TESTS sepsis trial.

Mechanism

Mechanism data for these substances is limited in the provided records. For Semaglutide, the clinical data describes its action in the context of GLP-1 RA-related effects, specifically delayed gastric emptying and its impact on weight and cardiovascular outcomes. Tesamorelin is noted for its ability to achieve an 18% reduction in visceral adipose tissue (VAT) in pivotal Phase III trials for HIV lipodystrophy.

Limitations of the Evidence

There is a significant lack of human exposure and safety data for several peptides including BPC-157 and TB-500. Many safety signals for approved peptides like Semaglutide are derived from postmarketing surveillance (FAERS), which may be subject to reporting bias and requires formal clinical validation. For substances like Selank and Semax, clinical data in the provided records is restricted to their approved status in Russia, with no FDA-recognized safety data available. The clinical utility of Thymosin Alpha-1 is limited by negative results in large-scale mortality trials for sepsis.

Clinical Takeaway

Physicians should note that many peptides frequently utilized in clinical settings, such as BPC-157 and CJC-1295, are classified by the FDA as Category 2 substances due to immunogenicity concerns or safety signals like tachycardia. For approved GLP-1 RAs, clinicians must monitor for established GI effects and emerging risks including NAION and pulmonary aspiration during anesthesia. Compounded versions of these peptides are subject to strict regulatory scrutiny and multiple warning letters have been issued regarding their unapproved distribution.

This content is sourced exclusively from TruthTides clinical reference data and does not constitute medical advice.

Sources

• REGULATORY STATUS RECORDS (BPC-157, Thymosin Alpha-1, TB-500, AOD-9604, CJC-1295, Ipamorelin, Selank, Semax, GHK-Cu, GHRP-2)
• FAERS SAFETY SIGNALS (Semaglutide 2023-2025)
• CLINICAL TRIAL RECORDS (NCT03548935, NCT03574597, NCT04184622, NCT05024032, NCT04881706, NCT00451282, NCT02867267)